Cytokinetics, Incorporated
CYTK
Rang in aandelen
#2260
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Aandeelprijs
$64.11
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$8.91B
Verandering (1 dag)
2.34%
Verandering (1 jaar)
10.96%
Land
US
Handel Cytokinetics, Incorporated (CYTK)
Categorie
Healthcare
Omzet van Cytokinetics, Incorporated (CYTK)
Omzet in Jun 2026 TTM: $70.96M
Volgens de laatste financiële rapporten van Cytokinetics, Incorporated bedraagt de huidige omzet van het bedrijf (TTM) $70.96M. In 2023 behaalde het bedrijf een omzet van $7.53M een daling ten opzichte van de omzet in het jaar 2022, die $94.59M bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Cytokinetics, Incorporated van 2000 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2026 (TTM) | $70.96M | 284.11% |
| 2024 | $18.47M | 145.34% |
| 2023 | $7.53M | -92.04% |
| 2022 | $94.59M | 34.30% |
| 2021 | $70.43M | 26.15% |
| 2020 | $55.83M | 107.79% |
| 2019 | $26.87M | -14.71% |
| 2018 | $31.50M | 135.64% |
| 2017 | $13.37M | -87.44% |
| 2016 | $106.41M | 271.30% |
| 2015 | $28.66M | -38.95% |
| 2014 | $46.94M | 53.16% |
| 2013 | $30.65M | 305.45% |
| 2012 | $7.56M | 88.98% |
| 2011 | $4.00M | 55.22% |
| 2010 | $2.58M | -96.84% |
| 2009 | $81.54M | 556.51% |
| 2008 | $12.42M | -8.82% |
| 2007 | $13.62M | 335.63% |
| 2006 | $3.13M | -64.91% |
| 2005 | $8.91M | -33.70% |
| 2004 | $13.44M | 27.09% |
| 2003 | $10.58M | -7.19% |
| 2002 | $11.40M | 34.61% |
| 2001 | $8.47M | 0.00% |
| 2000 | 0.00 | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| $12.62B | 17,690.73% |
US
|
|
| $2.23B | 3,039.80% |
US
|
|
| $15.74B | 22,087.61% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 8,385.47% |
NL
|
